Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
PFZ On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
Stockholm
London
All times are local (Market data is delayed by at least 15 minutes).

Transactions by PFIZER INC (PFZ) in the last 6 months

Announced 08/24/15
Pfizer Inc., Four Pharmaceutical Products
Merger/Acquisition

Alvogen, Inc. agreed to acquire Four Pharmaceutical Products from Pfizer Inc. (NYSE:PFE) on August 24, 2015. The assets being acquired include an attractive portfolio of three injectable products and one inhaled solution product. Two are on-market products, Clindamycin injection and Acetylcysteine inhalation solution. Acetylcysteine will continue to be marketed by Fresenius with Alvogen receiving profit sharing payments. In addition, Alvogen will acquire two pending ...
Read More


PFZ's price was unchanged after the transaction was announced on 08/24/15.
Investor / Buyer
Alvogen, Inc.
Creditor / Lender
Pfizer Inc.
 
Announced 07/2/15
11.00M for Icagen, Inc.
Merger/Acquisition

XRpro Sciences, Inc. entered into an asset purchase agreement to acquire Icagen, Inc from Pfizer Inc. (NYSE:PFE) for $11 million on June 26, 2015. Under the terms of the agreement, XRpro agreed to pay: (i) an upfront cash purchase price of $0.5 million, of which $0.125 million was paid at closing date, and $0.375 million is to be paid in three equal installments of $0.125 million, on September 1, 2015, December 1, 2015 and March 1, 2016; (ii) a cash payment of $0.5 million ...
Read More


PFZ's price was unchanged after the transaction was announced on 07/2/15.
Investor / Buyer
XRpro Sciences, Inc.
Creditor / Lender
Pfizer Inc.
 
Announced 05/11/15
AM-Pharma B.V.
Merger/Acquisition

Pfizer Inc. (NYSE:PFE) acquired 17.5% stake in AM-Pharma B.V. on May 11, 2015. Pfizer Inc. acquired minority stake and an exclusive option to acquire the remaining equity in AM-Pharma. Pfizer made an upfront payment of $87.5 million for the minority equity interest and exclusive option, with additional potential payments of up to $512.5 million upon option exercise and potential launch of any product that may result from this agreement. Clifford Chance LLP and Jonathan ...
Read More


PFZ's price was unchanged after the transaction was announced on 05/11/15.
Investor / Buyer
Pfizer Inc.
Legal Advisor
Clifford Chance LLP
Dechert LLP
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFZ:LN $0.00 USD 0.00

PFZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €117.42 EUR -4.46
Gilead Sciences Inc $102.06 USD +0.15
Johnson & Johnson $91.31 USD -1.33
Nestle SA SFr.70.55 CHF -0.55
Procter & Gamble Co/The $68.76 USD -1.17
View Industry Companies
 

Industry Analysis

PFZ

Industry Average

Valuation PFZ Industry Range
Price/Earnings 22.7x
Price/Sales 4.1x
Price/Book 2.9x
Price/Cash Flow 15.6x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.